All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel 
.
| Security |
Imputed
Share Price |
Prev
Shares |
Current
Shares |
Change
(Percent) |
Prev Value
(USD x1000) |
Current Value
(USD x1000) |
Change
(Percent) |
|---|
| CNTB / Connect Biopharma Holdings Limited - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| CRDF / Cardiff Oncology, Inc.
|
|
|
|
|
|
|
|
| EWTX / Edgewise Therapeutics, Inc.
|
|
|
|
|
|
|
|
| HLXA / Helix Acquisition Corp - Class A
|
|
|
|
|
|
|
|
| AMAM / Ambrx Biopharma Inc.
|
|
|
|
|
|
|
|
| IKNA / Ikena Oncology, Inc.
|
|
|
|
|
|
|
|
| JYAC / Jiya Acquisition Corp - Class A
|
|
|
|
|
|
|
|
| KRON / Kronos Bio, Inc.
|
|
|
|
|
|
|
|
| KYMR / Kymera Therapeutics, Inc.
|
|
|
|
|
|
|
|
| NGM / NGM Biopharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| DSGN / Design Therapeutics, Inc.
|
|
|
|
|
|
|
|
| CRIS / Curis, Inc.
|
|
|
|
|
|
|
|
| RNA / Avidity Biosciences, Inc.
|
|
|
|
|
|
|
|
| XLRN / Acceleron Pharma Inc
|
|
|
|
|
|
|
|
| ZLAB / Zai Lab Limited - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| VERA / Vera Therapeutics, Inc.
|
|
|
|
|
|
|
|
| RXDX / Prometheus Biosciences Inc
|
|
|
|
|
|
|
|
| IMAB / I-Mab - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| FDMT / 4D Molecular Therapeutics, Inc.
|
|
|
|
|
|
|
|
| RVMD / Revolution Medicines, Inc.
|
|
|
|
|
|
|
|
| CCXI / ChemoCentryx Inc
|
|
|
|
|
|
|
|
| RCUS / Arcus Biosciences, Inc.
|
|
|
|
|
|
|
|
| GLUE / Monte Rosa Therapeutics, Inc.
|
|
|
|
|
|
|
|
| CLDX / Celldex Therapeutics, Inc.
|
|
|
|
|
|
|
|
| ARVN / Arvinas, Inc.
|
|
|
|
|
|
|
|
| STOK / Stoke Therapeutics, Inc.
|
|
|
|
|
|
|
|
| FHTX / Foghorn Therapeutics Inc.
|
|
|
|
|
|
|
|
| BBIO / BridgeBio Pharma, Inc.
|
|
|
|
|
|
|
|
| ISEE / IVERIC bio Inc
|
|
|
|
|
|
|
|
| MRUS / Merus N.V.
|
|
|
|
|
|
|
|
| PMVP / PMV Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| GOSS / Gossamer Bio, Inc.
|
|
|
|
|
|
|
|
| APLS / Apellis Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| DYN / Dyne Therapeutics, Inc.
|
|
|
|
|
|
|
|
| IPSC / Century Therapeutics, Inc.
|
|
|
|
|
|
|
|
| TSHA / Taysha Gene Therapies, Inc.
|
|
|
|
|
|
|
|
